You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
昭衍新藥(603127.SH)擬投資11億元建設昭衍(廣州)新藥評價中心
格隆匯 12-11 16:25

格隆匯12月11日丨昭衍新藥(603127.SH)公佈,基於未來業務拓展需要,公司擬與廣州市開發區管理委員會開展合作,在廣州市投資建設昭衍(廣州)新藥評價中心項目,以擴大公司在華南地區的醫藥研發外包服務範圍和影響力,總投資規模約為人民幣11億元。

本次投資是公司基於長期發展的戰略考量,短期內對公司財務狀況及業績不會產生重大影響。我國華南地區特別是廣東、深圳地區的新藥研發不斷活躍,對新藥臨牀前安全性評價服務的需求也在不斷提高,然而華南地區缺乏高度專業的新藥評價GLP機構及服務能力,該項目的建設,從長期來看,可以充實華南地區新藥安全性評價的服務力量,有利於公司擴大在華南地區的影響力,從而增強公司的整體醫藥研發外包服務競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account